Monday’s Mid-Day Movers: American Midstream Partners LP (AMID), Tenet Healthcare Corp (THC), Glu Mobile Inc. (GLUU), and Agios Pharmaceuticals Inc (AGIO)


American Midstream Partners LP (NYSE:AMID) is up more than 35% at mid-day after the pipeline company announced a $75 million unit purchase program, approved by ArcLight. The purchases will begin as early as tomorrow. According to TipRanks, one analyst currently recommends buying AMID while one other analyst remains on the sidelines. The average 12-month price target between these two analysts is $11.25, marking a 100% potential upside from current levels.

Tenet Healthcare Corp (NYSE:THC) is up more than 9% at mid-day after the healthcare company recently signed a four year agreement with Aetna; an extension of the current partnership. Three analysts on TipRanks have rated the company in the last three months. One analyst is bullish on the company and two remain neutral. The average 12-month price target between these 3 analysts is $38, marking a 27% potential upside from current levels.

Glu Mobile Inc. (NASDAQ:GLUU) is down 20% at mid-day, hitting a 52-week low. This drop comes a few days after the company released “Katy Perry Pop,” the newest game in a series focusing on celebrities. The stock had risen before the game’s release in anticipation, but the new game revealed several issues, prompting bad reviews. According to the 6 analysts polled by TipRanks, 2 are bullish on the company while 4 remain neutral. The average 12-month price target between these 6 analysts is $4.80, marking over a 100% potential upside from current levels.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) is up more than 10% at mid-day following Friday’s announcement that the company initiated Phase 1b trial of its pipeline drug intended for patients with acute myeloid leukemia, or AML. The pipeline drug, AG-221 or AG-120 in combination with intensive chemotherapy, is being developed with Celgene. All 4 analysts polled by TipRanks in the last 3 months are neutral on Agios with an average 12-month price target of $69, marking a 12% potential upside from current levels.